Experience in treating portal thromboses in patients with chronic myeloproliferative diseases
Patients with myeloproliferative diseases (MPD) are noted to be at high risk for portal thromboses. This problem gives rise to disability if it is untimely treated or resistant to therapy. The paper gives the experience of the Outpatient Department of the Hematology Research Center, Ministry of Heal...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2016-01-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/31926/pdf |
id |
doaj-c39a8eeb2d024e029564869ef450ef47 |
---|---|
record_format |
Article |
spelling |
doaj-c39a8eeb2d024e029564869ef450ef472020-11-25T03:50:10Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422016-01-01881899528942Experience in treating portal thromboses in patients with chronic myeloproliferative diseasesA L MelikyanG A SukhanovaM V VakhrushevaI N SubortsevaE B OrelPatients with myeloproliferative diseases (MPD) are noted to be at high risk for portal thromboses. This problem gives rise to disability if it is untimely treated or resistant to therapy. The paper gives the experience of the Outpatient Department of the Hematology Research Center, Ministry of Health of the Russian Federation, in using antithrombin III in MPD patients (3 patients with primary myelofibrosis, 3 with essential thrombocythemia) and acute and subacute portal vein thromboses resistant to therapy with direct anticoagulants. In all 5 cases, the use of antithrombin III in combination with low-molecular-weight heparin showed a positive clinical effect as rapid relief of pain syndrome and comparatively early (3-week to 1.5—2-month) recanalization of thrombosed vessels. Three clinical cases are described in detail.https://ter-arkhiv.ru/0040-3660/article/viewFile/31926/pdfantithrombin iiithrombosisthrombophiliachronic myeloproliferative diseasespolycythemia veraessential thrombocythemiaprimary myelofibrosisjak2 v617f mutationtreatment of thromboses |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
A L Melikyan G A Sukhanova M V Vakhrusheva I N Subortseva E B Orel |
spellingShingle |
A L Melikyan G A Sukhanova M V Vakhrusheva I N Subortseva E B Orel Experience in treating portal thromboses in patients with chronic myeloproliferative diseases Терапевтический архив antithrombin iii thrombosis thrombophilia chronic myeloproliferative diseases polycythemia vera essential thrombocythemia primary myelofibrosis jak2 v617f mutation treatment of thromboses |
author_facet |
A L Melikyan G A Sukhanova M V Vakhrusheva I N Subortseva E B Orel |
author_sort |
A L Melikyan |
title |
Experience in treating portal thromboses in patients with chronic myeloproliferative diseases |
title_short |
Experience in treating portal thromboses in patients with chronic myeloproliferative diseases |
title_full |
Experience in treating portal thromboses in patients with chronic myeloproliferative diseases |
title_fullStr |
Experience in treating portal thromboses in patients with chronic myeloproliferative diseases |
title_full_unstemmed |
Experience in treating portal thromboses in patients with chronic myeloproliferative diseases |
title_sort |
experience in treating portal thromboses in patients with chronic myeloproliferative diseases |
publisher |
"Consilium Medicum" Publishing house |
series |
Терапевтический архив |
issn |
0040-3660 2309-5342 |
publishDate |
2016-01-01 |
description |
Patients with myeloproliferative diseases (MPD) are noted to be at high risk for portal thromboses. This problem gives rise to disability if it is untimely treated or resistant to therapy. The paper gives the experience of the Outpatient Department of the Hematology Research Center, Ministry of Health of the Russian Federation, in using antithrombin III in MPD patients (3 patients with primary myelofibrosis, 3 with essential thrombocythemia) and acute and subacute portal vein thromboses resistant to therapy with direct anticoagulants. In all 5 cases, the use of antithrombin III in combination with low-molecular-weight heparin showed a positive clinical effect as rapid relief of pain syndrome and comparatively early (3-week to 1.5—2-month) recanalization of thrombosed vessels. Three clinical cases are described in detail. |
topic |
antithrombin iii thrombosis thrombophilia chronic myeloproliferative diseases polycythemia vera essential thrombocythemia primary myelofibrosis jak2 v617f mutation treatment of thromboses |
url |
https://ter-arkhiv.ru/0040-3660/article/viewFile/31926/pdf |
work_keys_str_mv |
AT almelikyan experienceintreatingportalthrombosesinpatientswithchronicmyeloproliferativediseases AT gasukhanova experienceintreatingportalthrombosesinpatientswithchronicmyeloproliferativediseases AT mvvakhrusheva experienceintreatingportalthrombosesinpatientswithchronicmyeloproliferativediseases AT insubortseva experienceintreatingportalthrombosesinpatientswithchronicmyeloproliferativediseases AT eborel experienceintreatingportalthrombosesinpatientswithchronicmyeloproliferativediseases |
_version_ |
1724491864297439232 |